Is tesamorelin approved for weight loss?
As Egrifta, it’s approved to reduce excess abdominal fat in adults with HIV and lipodystrophy. The label says it isn’t a treatment for general weight-loss management.
15 of 16 in Every Peptide Explained in 10 Minutes (Human Studies Only)
What the human studies found
- Sold online for fat loss and growth hormone.
- Tesamorelin is the active ingredient in Egrifta, approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, a condition that changes how the body stores fat.
- The label specifically says it isn’t indicated for weight-loss management.
- An approval belongs to a particular medicine and a particular use. It doesn’t spread to every bottle with a matching name.
The studies (2)
Also cited
We checked the human research behind 16 peptides. The question wasn’t just “is there a study?” It was “does that study support the pitch?” For each one: who took part, what was measured, and what actually changed.
Watch all 16, explained: the film on YouTube · 9:42An approval, a trial or a paper belongs to a particular substance and a particular use. None of it verifies the contents of a bottle sold online. This is an investigation of the claims, not a guide to taking them.
Get the free 3-question checklist
The three questions we asked of all 16 peptides, plus each new investigation when it drops. No spam, unsubscribe anytime.